CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) shares passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.23 and traded as low as $0.1890. CytoDyn shares last traded at $0.1971, with a volume of 1,222,842 shares changing hands.
CytoDyn Stock Performance
The business’s 50 day simple moving average is $0.23 and its 200-day simple moving average is $0.27. The company has a market cap of $274.76 million, a price-to-earnings ratio of -6.65 and a beta of 1.18.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Further Reading
- Five stocks we like better than CytoDyn
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
